U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C15H24N4O6S2.H2O
Molecular Weight 438.52
Optical Activity UNSPECIFIED
Defined Stereocenters 6 / 6
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of DORIPENEM MONOHYDRATE

SMILES

O.[H][C@]12[C@@H](C)C(S[C@@H]3CN[C@H](CNS(N)(=O)=O)C3)=C(N1C(=O)[C@]2([H])[C@@H](C)O)C(O)=O

InChI

InChIKey=NTUBEBXBDGKBTJ-WGLOMNHJSA-N
InChI=1S/C15H24N4O6S2.H2O/c1-6-11-10(7(2)20)14(21)19(11)12(15(22)23)13(6)26-9-3-8(17-5-9)4-18-27(16,24)25;/h6-11,17-18,20H,3-5H2,1-2H3,(H,22,23)(H2,16,24,25);1H2/t6-,7-,8+,9+,10-,11-;/m1./s1

HIDE SMILES / InChI

Molecular Formula C15H24N4O6S2
Molecular Weight 420.504
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 6 / 6
E/Z Centers 0
Optical Activity UNSPECIFIED

Molecular Formula H2O
Molecular Weight 18.0153
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Sources: www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4364b1-02-johnson.pdf
Curator's Comment: Description was created based on several sources including http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2446428/#B1

Doripenem is a synthetic carbapenem that has broad antibacterial potency against aerobic and anaerobic gram-positive and gram-negative bacteria. Doripenem is structurally related to beta-lactam antibiotics and shares the bactericidal mode of action of other β-lactam antibiotics by targeting penicillin-binding proteins (PBPs) to inhibit the biosynthesis of the bacterial cell wall. Doripenem is resistant to hydrolysis by most β-lactamases and is resistant to inactivation by renal dehydropeptidases. Doripenem has many similarities to the other carbapenems, as well as some important differences, such as greater potency against Pseudomonas aeruginosa. It was found to be similar to comparator agents. The most common adverse effects related to doripenem therapy were headache, nausea, diarrhea, rash, and phlebitis.

CNS Activity

Curator's Comment: Doripenem penetrates the intact blood-brain barrier to a small but measurable extent.

Originator

Curator's Comment: Shionogi (Japan) is the drug's originator and markets doripenem under the brand name Finibax. Peninsula Pharmaceuticals acquired development and marketing rights to doripenem in the US in a licensing agreement signed with Shionogi in 2003. Doripenem is part of Johnson &' Johnson's anti-infective R&D portfolio following the acquisition of Peninsula Pharmaceuticals in 2005.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
47.6 µM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
DORIBAX

Approved Use

Indicated as a single agent for the treatment of complicated intra-abdominal infections caused by Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Bacteroides caccae, Bacteroides fragilis, Bacteroides thetaiotaomicron, Bacteroides uniformis, Bacteroides vulgatus, Streptococcus intermedius, Streptococcus constellatus and Peptostreptococcus micros and as a single agent for the treatment of complicated urinary tract infections, including pyelonephritis caused by Escherichia coli including cases with concurrent bacteremia, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, and Acinetobacter baumannii. To reduce the development of drug-resistant bacteria and maintain the effectiveness of DORIBAX® and other antibacterial drugs, DORIBAX® should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria.

Launch Date

2007
Curative
DORIBAX

Approved Use

Indicated as a single agent for the treatment of complicated intra-abdominal infections caused by Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Bacteroides caccae, Bacteroides fragilis, Bacteroides thetaiotaomicron, Bacteroides uniformis, Bacteroides vulgatus, Streptococcus intermedius, Streptococcus constellatus and Peptostreptococcus micros and as a single agent for the treatment of complicated urinary tract infections, including pyelonephritis caused by Escherichia coli including cases with concurrent bacteremia, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, and Acinetobacter baumannii. To reduce the development of drug-resistant bacteria and maintain the effectiveness of DORIBAX® and other antibacterial drugs, DORIBAX® should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria.

Launch Date

2007
Curative
DORIBAX

Approved Use

Indicated as a single agent for the treatment of complicated intra-abdominal infections caused by Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Bacteroides caccae, Bacteroides fragilis, Bacteroides thetaiotaomicron, Bacteroides uniformis, Bacteroides vulgatus, Streptococcus intermedius, Streptococcus constellatus and Peptostreptococcus micros and as a single agent for the treatment of complicated urinary tract infections, including pyelonephritis caused by Escherichia coli including cases with concurrent bacteremia, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, and Acinetobacter baumannii. To reduce the development of drug-resistant bacteria and maintain the effectiveness of DORIBAX® and other antibacterial drugs, DORIBAX® should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria.

Launch Date

2007
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
16.87 μg/mL
500 mg single, intravenous
dose: 500 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
DORIPENEM plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
12.94 μg/mL
500 mg single, intravenous
dose: 500 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
DORIPENEM plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
10.2 mg/L
250 mg single, intravenous
dose: 250 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
DORIPENEM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
23 μg/mL
500 mg single, intravenous
dose: 500 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
DORIPENEM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
52.98 μg × h/mL
500 mg single, intravenous
dose: 500 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
DORIPENEM plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
70.64 μg × h/mL
500 mg single, intravenous
dose: 500 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
DORIPENEM plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
13.8 mg × h/L
250 mg single, intravenous
dose: 250 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
DORIPENEM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
36.3 μg × h/mL
500 mg single, intravenous
dose: 500 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
DORIPENEM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
47.1 mg*h/L
500 mg 1 times / 8 hour multiple, intravenous
dose: 500 mg
route of administration: intravenous
experiment type: multiple
co-administered:
DORIPENEM serum
Homo sapiens
population: unhealthy
age:
sex:
food status:
66.4 mg*h/L
1000 mg 1 times / 8 hour multiple, intravenous
dose: 1000 mg
route of administration: intravenous
experiment type: multiple
co-administered:
DORIPENEM serum
Homo sapiens
population: unhealthy
age:
sex:
food status:
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
2.93 h
500 mg single, intravenous
dose: 500 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
DORIPENEM plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
4.04 h
500 mg single, intravenous
dose: 500 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
DORIPENEM plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
0.91 h
250 mg single, intravenous
dose: 250 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
DORIPENEM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
1 h
500 mg single, intravenous
dose: 500 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
DORIPENEM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
2.2 h
500 mg 1 times / 8 hour multiple, intravenous
dose: 500 mg
route of administration: intravenous
experiment type: multiple
co-administered:
DORIPENEM serum
Homo sapiens
population: unhealthy
age:
sex:
food status:
2.4 h
1000 mg 1 times / 8 hour multiple, intravenous
dose: 1000 mg
route of administration: intravenous
experiment type: multiple
co-administered:
DORIPENEM serum
Homo sapiens
population: unhealthy
age:
sex:
food status:
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
91.9%
500 mg single, intravenous
dose: 500 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
DORIPENEM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
2 g 3 times / day multiple, intravenous
Highest studied dose
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, 24 years (rangeL 21–37 years)
n = 16
Health Status: unhealthy
Condition: cystic fibrosis
Age Group: 24 years (rangeL 21–37 years)
Sex: M+F
Population Size: 16
Sources:
Disc. AE: Transaminases increased, Allergic reaction...
Other AEs: Leukopenia, Diarrhea...
AEs leading to
discontinuation/dose reduction:
Transaminases increased (1 patient)
Allergic reaction (1 patient)
Other AEs:
Leukopenia (1 patient)
Diarrhea (11 patient)
Nausea (9 patients)
Vomiting (9 patients)
Headache (6 patients)
Oral candidiasis (3 patients)
Rash (2 patients)
Sources:
500 mg 3 times / day steady, intravenous
Recommended
Dose: 500 mg, 3 times / day
Route: intravenous
Route: steady
Dose: 500 mg, 3 times / day
Sources:
unhealthy, 54 years (range: 18-90 years)
n = 853
Health Status: unhealthy
Condition: intra-abdominal infections
Age Group: 54 years (range: 18-90 years)
Sex: M+F
Population Size: 853
Sources:
Disc. AE: Nausea, Vulval mycotic infection...
AEs leading to
discontinuation/dose reduction:
Nausea (0.2%)
Vulval mycotic infection (0.1%)
Rash (0.1%)
Sources:
5 mg/kg single, intravenous
Dose: 5 mg/kg
Route: intravenous
Route: single
Dose: 5 mg/kg
Sources:
unknown, <8 weeks
n = 26
Health Status: unknown
Age Group: <8 weeks
Sex: M+F
Population Size: 26
Sources:
Other AEs: Anemia neonatal, Hypoalbuminemia...
Other AEs:
Anemia neonatal (3 patients)
Hypoalbuminemia (3 patients)
Hyperglycemia (2 patients)
Peripheral edema (1 patient)
Patent ductus arteriosus (2 patients)
Sources:
8 mg/kg single, intravenous
Dose: 8 mg/kg
Route: intravenous
Route: single
Dose: 8 mg/kg
Sources:
unknown, >8 weeks <44 weeks
n = 26
Health Status: unknown
Age Group: >8 weeks <44 weeks
Sex: M+F
Population Size: 26
Sources:
Other AEs: Anemia neonatal, Peripheral edema...
Other AEs:
Anemia neonatal (1 patient)
Peripheral edema (1 patient)
Dermatitis diaper (2 patients)
Sources:
AEs

AEs

AESignificanceDosePopulation
Leukopenia 1 patient
2 g 3 times / day multiple, intravenous
Highest studied dose
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, 24 years (rangeL 21–37 years)
n = 16
Health Status: unhealthy
Condition: cystic fibrosis
Age Group: 24 years (rangeL 21–37 years)
Sex: M+F
Population Size: 16
Sources:
Allergic reaction 1 patient
Disc. AE
2 g 3 times / day multiple, intravenous
Highest studied dose
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, 24 years (rangeL 21–37 years)
n = 16
Health Status: unhealthy
Condition: cystic fibrosis
Age Group: 24 years (rangeL 21–37 years)
Sex: M+F
Population Size: 16
Sources:
Transaminases increased 1 patient
Disc. AE
2 g 3 times / day multiple, intravenous
Highest studied dose
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, 24 years (rangeL 21–37 years)
n = 16
Health Status: unhealthy
Condition: cystic fibrosis
Age Group: 24 years (rangeL 21–37 years)
Sex: M+F
Population Size: 16
Sources:
Diarrhea 11 patient
2 g 3 times / day multiple, intravenous
Highest studied dose
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, 24 years (rangeL 21–37 years)
n = 16
Health Status: unhealthy
Condition: cystic fibrosis
Age Group: 24 years (rangeL 21–37 years)
Sex: M+F
Population Size: 16
Sources:
Rash 2 patients
2 g 3 times / day multiple, intravenous
Highest studied dose
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, 24 years (rangeL 21–37 years)
n = 16
Health Status: unhealthy
Condition: cystic fibrosis
Age Group: 24 years (rangeL 21–37 years)
Sex: M+F
Population Size: 16
Sources:
Oral candidiasis 3 patients
2 g 3 times / day multiple, intravenous
Highest studied dose
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, 24 years (rangeL 21–37 years)
n = 16
Health Status: unhealthy
Condition: cystic fibrosis
Age Group: 24 years (rangeL 21–37 years)
Sex: M+F
Population Size: 16
Sources:
Headache 6 patients
2 g 3 times / day multiple, intravenous
Highest studied dose
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, 24 years (rangeL 21–37 years)
n = 16
Health Status: unhealthy
Condition: cystic fibrosis
Age Group: 24 years (rangeL 21–37 years)
Sex: M+F
Population Size: 16
Sources:
Nausea 9 patients
2 g 3 times / day multiple, intravenous
Highest studied dose
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, 24 years (rangeL 21–37 years)
n = 16
Health Status: unhealthy
Condition: cystic fibrosis
Age Group: 24 years (rangeL 21–37 years)
Sex: M+F
Population Size: 16
Sources:
Vomiting 9 patients
2 g 3 times / day multiple, intravenous
Highest studied dose
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, 24 years (rangeL 21–37 years)
n = 16
Health Status: unhealthy
Condition: cystic fibrosis
Age Group: 24 years (rangeL 21–37 years)
Sex: M+F
Population Size: 16
Sources:
Rash 0.1%
Disc. AE
500 mg 3 times / day steady, intravenous
Recommended
Dose: 500 mg, 3 times / day
Route: intravenous
Route: steady
Dose: 500 mg, 3 times / day
Sources:
unhealthy, 54 years (range: 18-90 years)
n = 853
Health Status: unhealthy
Condition: intra-abdominal infections
Age Group: 54 years (range: 18-90 years)
Sex: M+F
Population Size: 853
Sources:
Vulval mycotic infection 0.1%
Disc. AE
500 mg 3 times / day steady, intravenous
Recommended
Dose: 500 mg, 3 times / day
Route: intravenous
Route: steady
Dose: 500 mg, 3 times / day
Sources:
unhealthy, 54 years (range: 18-90 years)
n = 853
Health Status: unhealthy
Condition: intra-abdominal infections
Age Group: 54 years (range: 18-90 years)
Sex: M+F
Population Size: 853
Sources:
Nausea 0.2%
Disc. AE
500 mg 3 times / day steady, intravenous
Recommended
Dose: 500 mg, 3 times / day
Route: intravenous
Route: steady
Dose: 500 mg, 3 times / day
Sources:
unhealthy, 54 years (range: 18-90 years)
n = 853
Health Status: unhealthy
Condition: intra-abdominal infections
Age Group: 54 years (range: 18-90 years)
Sex: M+F
Population Size: 853
Sources:
Peripheral edema 1 patient
5 mg/kg single, intravenous
Dose: 5 mg/kg
Route: intravenous
Route: single
Dose: 5 mg/kg
Sources:
unknown, <8 weeks
n = 26
Health Status: unknown
Age Group: <8 weeks
Sex: M+F
Population Size: 26
Sources:
Hyperglycemia 2 patients
5 mg/kg single, intravenous
Dose: 5 mg/kg
Route: intravenous
Route: single
Dose: 5 mg/kg
Sources:
unknown, <8 weeks
n = 26
Health Status: unknown
Age Group: <8 weeks
Sex: M+F
Population Size: 26
Sources:
Patent ductus arteriosus 2 patients
5 mg/kg single, intravenous
Dose: 5 mg/kg
Route: intravenous
Route: single
Dose: 5 mg/kg
Sources:
unknown, <8 weeks
n = 26
Health Status: unknown
Age Group: <8 weeks
Sex: M+F
Population Size: 26
Sources:
Anemia neonatal 3 patients
5 mg/kg single, intravenous
Dose: 5 mg/kg
Route: intravenous
Route: single
Dose: 5 mg/kg
Sources:
unknown, <8 weeks
n = 26
Health Status: unknown
Age Group: <8 weeks
Sex: M+F
Population Size: 26
Sources:
Hypoalbuminemia 3 patients
5 mg/kg single, intravenous
Dose: 5 mg/kg
Route: intravenous
Route: single
Dose: 5 mg/kg
Sources:
unknown, <8 weeks
n = 26
Health Status: unknown
Age Group: <8 weeks
Sex: M+F
Population Size: 26
Sources:
Anemia neonatal 1 patient
8 mg/kg single, intravenous
Dose: 8 mg/kg
Route: intravenous
Route: single
Dose: 8 mg/kg
Sources:
unknown, >8 weeks <44 weeks
n = 26
Health Status: unknown
Age Group: >8 weeks <44 weeks
Sex: M+F
Population Size: 26
Sources:
Peripheral edema 1 patient
8 mg/kg single, intravenous
Dose: 8 mg/kg
Route: intravenous
Route: single
Dose: 8 mg/kg
Sources:
unknown, >8 weeks <44 weeks
n = 26
Health Status: unknown
Age Group: >8 weeks <44 weeks
Sex: M+F
Population Size: 26
Sources:
Dermatitis diaper 2 patients
8 mg/kg single, intravenous
Dose: 8 mg/kg
Route: intravenous
Route: single
Dose: 8 mg/kg
Sources:
unknown, >8 weeks <44 weeks
n = 26
Health Status: unknown
Age Group: >8 weeks <44 weeks
Sex: M+F
Population Size: 26
Sources:
Overview

Overview

Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
no
no
no
no
no
no
no
no
no
no
unlikely
unlikely
unlikely
unlikely
unlikely
unlikely
Drug as victim

Drug as victim

Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Doripenem: S 4661.
2003
Doripenem (S-4661), a novel carbapenem: comparative activity against contemporary pathogens including bactericidal action and preliminary in vitro methods evaluations.
2004 Jul
Comparative in vitro antimicrobial activity of a new carbapenem, doripenem: tentative disc diffusion criteria and quality control.
2005 Jun
Antibacterial Drug Discovery and Development Summit - Tenth Annual SRI Summit.
2005 May
Study of the synergism between carbapenems and vancomycin or teicoplanin against MRSA, focusing on S-4661, a carbapenem newly developed in Japan.
2005 Oct
Acquisitions not a cure for anti-infectives.
2005 Sep
Occurrence of PER-1 producing clinical isolates of Pseudomonas aeruginosa in Japan and their susceptibility to doripenem.
2006 Dec
[New antibiotics for the therapy of respiratory tract infections].
2006 Jul
Clinical experience with recently approved antibiotics.
2006 Oct
[Analysis on the effective dosage regimens for meropenem, biapenem and doripenem against P. aeruginosa infection based on pharmacokinetics and pharmacodynamics theory].
2007 Dec
Peritoneal penetration of doripenem after intravenous administration in abdominal-surgery patients.
2007 Dec
Investigational treatments for postoperative surgical site infections.
2007 Feb
Development of an HPLC method for the determination of doripenem in human and mouse serum.
2007 Jun 15
Doripenem: A new carbapenem antibiotic a review of comparative antimicrobial and bactericidal activities.
2007 Oct
An overview of harms associated with beta-lactam antimicrobials: where do the carbapenems fit in?
2008
Pharmacodynamic optimization of beta-lactams in the patient care setting.
2008
[Clinical examination of doripenem for infectious diseases in gynecological and associated fields].
2008 Apr
Hospital resource utilization with doripenem versus imipenem in the treatment of ventilator-associated pneumonia.
2008 Apr
Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: a multicenter, randomized study.
2008 Apr
Current therapies for pseudomonas aeruginosa.
2008 Apr
Pharmacokinetic-pharmacodynamic modeling and simulation for in vivo bactericidal effect in murine infection model.
2008 Apr
[In-vitro activity of panipenem against clinical isolates in 2006].
2008 Feb
Multidrug-resistant Gram-negative bacterial infections: the emerging threat and potential novel treatment options.
2008 Feb
Doripenem (Doribax)--a new parenteral carbapenem.
2008 Jan 28
New drugs: doripenem, raltegravir, and ixabepilone.
2008 Jan-Feb
Activity of doripenem and comparator beta-lactams against US clinical isolates of Streptococcus pneumoniae with defined mutations in the penicillin-binding domains of pbp1a, pbp2b and pbp2x.
2008 Mar
Quantification of doripenem in human plasma and peritoneal fluid by high-performance liquid chromatography with ultraviolet detection.
2008 May 1
Non-susceptibility trends among Enterobacteriaceae from bacteraemias in the UK and Ireland, 2001-06.
2008 Nov
Pharmacodynamic assessment of doripenem in peritoneal fluid against Gram-negative organisms: use of population pharmacokinetic modeling and Monte Carlo simulation.
2008 Nov
Current treatment of pseudomonal infections in the elderly.
2009
Current status of newer carbapenems.
2009
Antimicrobial activities of doripenem and other carbapenems against Pseudomonas aeruginosa, other nonfermentative bacilli, and Aeromonas spp.
2009 Apr
New antibiotics for healthcare-associated pneumonia.
2009 Feb
Doripenem monohydrate, a broad-spectrum carbapenem antibiotic.
2009 Jan
Doripenem.
2009 Jul 15
Doripenem: position in clinical practice.
2009 Jun
Characterization of blaKPC-containing Klebsiella pneumoniae isolates detected in different institutions in the Eastern USA.
2009 Mar
Patents

Patents

Sample Use Guides

In Vivo Use Guide
Sources: www.accessdata.fda.gov/drugsatfda_docs/label/2013/022106s014lbl.pdf
Curator's Comment: Administered every 8 hours by intravenous infusion over one hour in patients ≥18 years of age. For complicated intra-abdominal infection 5-14 days, for complicated UTI, including pyelonephritis 10 days.
500 mg administered every 8 hours by intravenous infusion over one hour in patients ≥18 years of age; for complicated intra-abdominal infection 5–14 days, for complicated UTI, including pyelonephritis 10 days.
Route of Administration: Intravenous
In Vitro Use Guide
Sources: www.accessdata.fda.gov/cdrh_docs/reviews/k080019.pdf
HardyDisk™ Doripenem Antimicrobial Susceptibility Test Disks are used for semi-quantitative in vitro susceptibility testing by the agar diffusion test procedure (Kirby-Bauer) of rapidly growing and certain fastidious bacterial pathogens. The concentration of doripenem 10ug has been shown to be active against most isolates of the following microorganisms both in vitro and in clinical infections: Acinetobacter baumannii, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, Streptococcus constellatus, Streptococcus intermedius
Substance Class Chemical
Created
by admin
on Fri Dec 15 19:48:09 GMT 2023
Edited
by admin
on Fri Dec 15 19:48:09 GMT 2023
Record UNII
4B035T6NKT
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
DORIPENEM MONOHYDRATE
WHO-DD  
Common Name English
DRIPENEM HYDRATE
Common Name English
FINIBAX
Common Name English
DORIPENEM HYDRATE [MI]
Common Name English
DORIPENEM HYDRATE
JAN   MI  
Common Name English
Doripenem monohydrate [WHO-DD]
Common Name English
DORIPENEM HYDRATE [JAN]
Common Name English
(4R,5.BETA.)-3-(((3S)-5.BETA.-((SULFAMOYLAMINO)METHYL)PYRROLIDINE-3.BETA.-YL)THIO)-4.ALPHA.-METHYL-6.BETA.-((1R)-1-HYDROXYETHYL)-7-OXO-1-AZABICYCLO(3.2.0)HEPTA-2-ENE-2-CARBOXYLIC ACID HYDRATE
Common Name English
Classification Tree Code System Code
EMA ASSESSMENT REPORTS DORIBAX (WITHDRAWN: PNEUMONIA, VENTILATOR-ASSOCIATED)
Created by admin on Fri Dec 15 19:48:09 GMT 2023 , Edited by admin on Fri Dec 15 19:48:09 GMT 2023
Code System Code Type Description
DRUG BANK
DBSALT001609
Created by admin on Fri Dec 15 19:48:09 GMT 2023 , Edited by admin on Fri Dec 15 19:48:09 GMT 2023
PRIMARY
PUBCHEM
636377
Created by admin on Fri Dec 15 19:48:09 GMT 2023 , Edited by admin on Fri Dec 15 19:48:09 GMT 2023
PRIMARY
CAS
364622-82-2
Created by admin on Fri Dec 15 19:48:09 GMT 2023 , Edited by admin on Fri Dec 15 19:48:09 GMT 2023
PRIMARY
MERCK INDEX
m4744
Created by admin on Fri Dec 15 19:48:09 GMT 2023 , Edited by admin on Fri Dec 15 19:48:09 GMT 2023
PRIMARY Merck Index
SMS_ID
100000091561
Created by admin on Fri Dec 15 19:48:09 GMT 2023 , Edited by admin on Fri Dec 15 19:48:09 GMT 2023
PRIMARY
EVMPD
SUB26847
Created by admin on Fri Dec 15 19:48:09 GMT 2023 , Edited by admin on Fri Dec 15 19:48:09 GMT 2023
PRIMARY
EPA CompTox
DTXSID60957788
Created by admin on Fri Dec 15 19:48:09 GMT 2023 , Edited by admin on Fri Dec 15 19:48:09 GMT 2023
PRIMARY
FDA UNII
4B035T6NKT
Created by admin on Fri Dec 15 19:48:09 GMT 2023 , Edited by admin on Fri Dec 15 19:48:09 GMT 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
ANHYDROUS->SOLVATE
Related Record Type Details
ACTIVE MOIETY